Please assess the completion status of the following clinical trial:

Trial Title: Adding Liraglutide to High Dose Insulin: Breaking the Cycle

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus~* Insulin dose of \>1.8 units/kg/day (represents total daily insulin dose, regardless of formulation, regimen, number of daily shots)~* HbA1c ≥ 7.5% and ≤ 11%~* Age ≥ 18~* Stable comorbidities on stable treatment regimens~* Stable dose of all oral hypoglycemics for ≥ 3 months prior to enrollment~* Ability to provide informed consent before any trial-related activities~Exclusion Criteria:~* Type 1 diabetes mellitus~* Any contraindication to the MRI procedure (metallic implants, severe claustrophobia, pregnancy, unable to lie still on a hard table for the duration of the procedure, weight above 400 lb - limit of the MRI table, magnet's inner circumference smaller than the largest body circumference)~* History of any pancreatic disease as it might interfere with the pancreatic TG measurement (i.e. pancreatitis, tumors, cysts, type 1 diabetes, any pancreatic surgery)~* End Stage Renal Disease on dialysis due to increased risk of hypoglycemia, and possible interference with accurate measurement of HbA1c~* Incretin therapy (any GLP-1 agonist or DPP-IV inhibitor)~* Unstable or decompensated comorbidities~* Personal or family history of medullary thyroid carcinoma or MEN-2 syndrome~* Severe gastroparesis~* Pregnancy, breast feeding, intention to become pregnant, or not using adequate contraceptive measures~* Organ transplant recipient or waiting list candidate~* Steroid use (current or potential use during the trial)~* Known/suspected allergy to trial medication, excipients, or related products~* Contraindications to study medications, worded specifically as stated in the product's prescribing information~* Non-English speaking volunteers since no interpreters are available and the safety of the volunteers could be jeopardized if adequate and reliable communication is not possible.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Liraglutide (Type: ACTIVE_COMPARATOR): None
- Saline injection (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).